Detalles de la búsqueda
1.
Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study.
J Clin Rheumatol
; 28(5): 270-277, 2022 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35653615
2.
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Lancet
; 395(10230): 1126-1136, 2020 04 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32178766
3.
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Lancet
; 395(10230): 1115-1125, 2020 04 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32178765
4.
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies.
Rheumatology (Oxford)
; 60(11): 5337-5350, 2021 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33822898
5.
Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis.
Rheumatology (Oxford)
; 60(10): 4495-4507, 2021 10 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33493312
6.
Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial.
Value Health
; 23(10): 1281-1285, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33032770
7.
Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial.
Value Health
; 23(10): 1286-1291, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33032771
8.
Spinal mobility in the cervical and lumbar spine correlates with magnetic resonance imaging findings for inflammatory and structural changes in patients with active ankylosing spondylitis.
Clin Exp Rheumatol
; 38(3): 467-471, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32242806
9.
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
Lancet
; 391(10136): 2213-2224, 2018 06 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29893222
10.
Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Rheumatology (Oxford)
; 58(3): 441-446, 2019 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30412238
11.
Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis: Results Through Week 52 of the GO-ALIVE Study.
J Clin Rheumatol
; 28(8): 420-423, 2022 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35649533
12.
Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Ann Rheum Dis
; 74(3): 538-46, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24344160
13.
Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation.
Ann Rheum Dis
; 73(1): 161-9, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23300117
14.
Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial.
Ann Rheum Dis
; 73(11): 1968-74, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23904470
15.
Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
Ann Rheum Dis
; 73(10): 1811-8, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23897769
16.
Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.
Rheumatology (Oxford)
; 53(9): 1654-63, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24729398
17.
Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides.
J Clin Rheumatol
; 20(1): 1-10, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24356481
18.
The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Rheumatology (Oxford)
; 52(10): 1845-55, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23838027
19.
Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
Arthritis Rheum
; 64(7): 2068-77, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22238071
20.
Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study.
Rheumatol Ther
; 10(4): 983-999, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37322274